Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615000201572
Ethics application status
Approved
Date submitted
12/02/2015
Date registered
2/03/2015
Date last updated
26/03/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Using Micronutrients in Smoking Cessation Treatment: A Double-Blind Randomized Placebo-controlled trial.
Scientific title
Investigation in to the effect of a micronutrient supplement combined with standard Quitline New Zealand care on quit success, withdrawal symptoms and associated psychological measures during smoking cessation': a double-blind randomized placebo-controlled trial.
Secondary ID [1] 285348 0
none
Universal Trial Number (UTN)
Trial acronym
SCAN
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Nicotine addiction 293071 0
Condition category
Condition code
Alternative and Complementary Medicine 293346 293346 0 0
Other alternative and complementary medicine
Mental Health 293347 293347 0 0
Addiction

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Double blind randomized controlled trial (RCT) comparing a micronutrient (vitamins and minerals) supplement Daily Essential Nutrients (DEN) with a placebo during a smoking cessation intervention followed by an open-label phase. The intervention consists of standard Quitline New Zealand care combined with a micronutrient formula (DEN) containing 41 ingredients: The doses of each ingredient in one capsule are: Vitamin A (as retinyl palmitate) 384 IU
Vitamin C (as ascorbic acid) 40 mg
Vitamin D (as cholecalciferol) 200 IU
Vitamin E (as d-alpha tocopheryl succinate) 24 IU
Vitamin K (as phylloquinone) 6 mcg
Vitamin K (as menaquinone-7) 2 mcg
Thiamin (as thiamin mononitrate) 4 mg
Riboflavin 1.2 mg
Niacin (as niacinamide) 6 mg
Vitamin B6 (as pyridoxine hydrochloride) 4.6667 mg
Folate (as folic acid) 50 mcg
Folate (as L-methylfolate calcium) 50 mcg
Vitamin B12 (as methylcobalamin) 60 mcg
Biotin 72 mcg
Pantothenic acid (as d-calcium pantothenate) 2 mg
Calcium (as chelate) 88 mg
Iron (as chelate) 0.916 mg
Phosphorus (as chelate) 56 mg
Iodine (as chelate) 13.6 mcg
Magnesium (as chelate) 40 mg
Zinc (as chelate) 3.2 mg
Selenium (as chelate) 13.6 mcg
Copper (as chelate) 0.48 mg
Manganese (as chelate) 0.64 mg
Chromium (as chelate) 41.6 mcg
Molybdenum (as chelate) 9.6 mcg
Potassium (as chelate) 16 mg
Choline bitartrate 36 mg
Alpha-lipoic acid 33.333 mg
Shilajit 12.5 mg
Inositol 12 mg
Acetylcarnitine (as acetyl-L-carnitine hydrochloride) 4 mg
Grape seed extract 3 mg
Ginkgo biloba leaf extract 2.4 mg
Methionine (as L-methionine hydrochloride) 2 mgCysteine (as N-acetyl-L-cysteine) 2 mg
Germanium sesquioxide (as chelate) 1.38 mg
Boron (as chelate) 0.16 mg
Vanadium (as chelate) 0.0796 mg
Lithium orotate (as chelate) 0.0667 mg
Nickel (as chelate) 0.002 mg
Other ingredients:
Cellulose 49.122 mg
Glycine 45 mg
Citric acid 26.814 mg
Magnesium stearate 24 mg
Silicon dioxide 20 mg

Baseline phase: Participants will be recruited via advertising to complete an online questionnaire that will assess their eligibility for the study and collect their demographic information. Eligible participants will be invited to the laboratory for their first consultation. At this consultation information will be given to the participant about the study and if they agree to take part they will sign a consent form. Participants will then complete baseline questionnaires; Smoking history, FTND, mCEQ, AUTOS, TCQ-12, AUDIT-C, Self-efficacy, MNWS, WSWS, DASS-21, ASI, DEMF and side effects. Participant’s weight and blood pressure will also be measured at this consultation. During the two week baseline participants will complete a daily diary of MPSS withdrawal symptoms and the number of cigarettes consumed. After the two weeks (end of baseline) the participants will come back in to the laboratory and complete the questionnaires again, excluding the smoking history questionnaire.

Pre-quitting (second baseline) phase (4 weeks): Once baseline phase is completed participants will come in to the laboratory for a second time and receive a four weeks supply of capsules (randomized to placebo (n=40) or micronutrients (n=40)) in plain containers. On days 1-2 participants will take 1 capsule 3 times daily, day 3-4 2 capsules 3 times daily, 5-6 3 capsules 3 times daily. On day 7 they will have titrated up to their full dose of 12 capsules/day and will continue to take three doses of four capsules with food and plenty of water each day for the remainder of the trial. For the first and the last weeks of the pre-quitting phase participants will complete a daily diary of recordings identical to baseline. Participants will complete the same questionnaires as baseline at two and four weeks of this phase. This phase permits the assessment of micronutrient consumption on smoking and related symptoms and on psychological health and wellbeing prior to any quit attempt being made.

Smoking cessation phase (12 weeks): After four weeks of taking the capsules participants will begin a smoking cessation intervention following Quitline New Zealand's five-step program (with the exclusion of step 4 that involves Nicotine Replacement Therapy) and continue to consume the capsules for 12 weeks. This smoking cessation phase will begin on an agreed quit date. Participants will monitor withdrawal symptoms (MPSS) for the first month after their quit date, then again in weeks eight and 12 using the daily diary. Every two weeks participants will also receive an email to complete questionnaires. Every 4 weeks participants will come in to the laboratory to complete questionnaires, receive more capsules and measure breath carbon monoxide to confirm smoking abstinence. Smoking relapse will be monitored, and participants are instructed to contact the researcher if they inhale a cigarette and to record it in the diary. Any participant that recorded smoking for 3 days in a row is counted as having a relapse. Participants that relapse continue to consume capsules and the researcher will help them to set a new quit date. If a participant is not smoke free at week 8 of this phase they will be asked to start the open-label phase (4-weeks earlier).

Open-label phase (4 weeks): At the end of smoking cessation phase participants will come in to the laboratory. All participants (smoking/non-smoking) will be offered a four-week open label phase where they will all be placed on the micronutrient capsules (12/day). During this phase they will complete a daily diary. Participants who are still smoking will be contacted prior to this visit to make the start of this phase a new quit date for them to re-attempt to quit smoking. Two-weeks in to this phase participants will receive an email to complete questionnaires. At the end of this phase participants will come back in to the laboratory for the last time, complete questionnaires and discuss any smoking cessation techniques Quitline suggests for long-term abstinence. Participants will be followed up 2 months after this phase by completing online questionnaires and report any smoking.
Intervention code [1] 290264 0
Treatment: Other
Intervention code [2] 290265 0
Behaviour
Comparator / control treatment
Placebo: Consists of riboflavin, fiber acacia gum, maltodextrin, and cocoa powder.
Patients swallow 12 capsules a day divided in to three doses of four pills each dose for a total of 16 weeks (4-week capsule alone phase and 12-week smoking cessation phase) (if participants do not quit smoking open-label phase will begin after 12 weeks of taking capsules). Participants randomized to the placebo condition follow the same protocol as the DEN group.
Control group
Placebo

Outcomes
Primary outcome [1] 293180 0
Continuous abstinence from cigarette smoking at 12-weeks measured by self report and carbon monoxide (CO) test. Continuous abstinence is defined as: 12 weeks abstinence with no relapses (a relapse is defined as returning to a normal pattern of smoking for 3 days in a row).
Timepoint [1] 293180 0
End of smoking cessation phase (12-weeks)
Secondary outcome [1] 310511 0
Continuous abstinence from two weeks (two-week grace period) in smoking cessation phase to end of treatment at 12-weeks. Assessed using self-report and carbon monoxide (CO) test.
Timepoint [1] 310511 0
End of smoking cessation phase (12-weeks)
Secondary outcome [2] 310512 0
Continuous abstinence from the start of the smoking cessation phase to four and eight weeks of the phase. Assessed using self-report and carbon monoxide (CO) test.
Timepoint [2] 310512 0
Four and eight weeks of the smoking cessation phase.
Secondary outcome [3] 310513 0
Seven-day point prevalence at four, eight, and 12 weeks of smoking cessation phase and four-weeks of open-label phase. Assessed using self-report and carbon monoxide (CO) test.
Timepoint [3] 310513 0
Four, eight, and 12 weeks of smoking cessation phase and four-weeks of open-label phase.
Secondary outcome [4] 310514 0
Minnesota Nicotine withdrawal scale
Timepoint [4] 310514 0
Baseline, before and after pre-quitting, 2,4,6,8,10, and 12-weeks of the smoking cessation phase. Two and four weeks of open label phase. Six-month follow-up.
Secondary outcome [5] 310515 0
Depression Anxiety Sensitivity Scale-21
Timepoint [5] 310515 0
Baseline, before and after pre-quitting phase, 2,4,6,8,10, and 12-weeks of the smoking cessation phase. Two and four weeks of open label phase. Six-month follow-up.
Secondary outcome [6] 310516 0
Weight
Timepoint [6] 310516 0
Baseline, before and after pre-quitting phase, 4,8, and 12-weeks of the smoking cessation phase. Four weeks after the open-label phase. Measured using digital scales.
Secondary outcome [7] 310517 0
Fagerstrom Test for Nicotine Dependence
Timepoint [7] 310517 0
Baseline, before and after pre-quitting phase at the start of smoking cessation and after a relapse during smoking cessation phase and at 6-month follow up. Relapse is when a participant has normal smoking pattern for 3 continuous days.
Secondary outcome [8] 310521 0
Mood and Physical Symptoms Scale
Timepoint [8] 310521 0
Daily during baseline phase, first and last week of pre-quitting phase, weeks 1-4, week-8 and week-12 of smoking cessation phase. First and last week of open label phase.
Secondary outcome [9] 310522 0
AUDIT-C
Timepoint [9] 310522 0
Baseline, before and after pre-quitting phase, 2,4,6,8,10, and 12-weeks of the smoking cessation phase. Two and four weeks of open label phase. Six-month follow-up.
Secondary outcome [10] 310523 0
Smoking Self-Efficacy Questionnaire
Timepoint [10] 310523 0
Baseline, before and after pre-quitting phase at the start of smoking cessation and after a relapse during smoking cessation phase and at 6-month follow up. Relapse is when a participant has normal smoking pattern for 3 continuous days.
Secondary outcome [11] 310524 0
Wisconsin Smoking Withdrawal Scale
Timepoint [11] 310524 0
Baseline, before and after pre-quitting phase, 2,4,6,8,10, and 12-weeks of the smoking cessation phase. Two and four weeks of open label phase. Six-month follow-up.
Secondary outcome [12] 310526 0
Diener and Emmons Mood Form
Timepoint [12] 310526 0
Baseline, before and after pre-quitting phase, 2,4,6,8,10, and 12-weeks of the smoking cessation phase. Two and four weeks of open label phase. Six-month follow-up.
Secondary outcome [13] 310527 0
Number of cigarettes smoked per day
Timepoint [13] 310527 0
Daily during baseline phase, first and last week of pre-quitting phase, weeks 1-4, week-8 and week-12 of smoking cessation phase. First and last week of the open-label phase. Assessed using self report in the daily diary.
Secondary outcome [14] 310528 0
Breath Carbon Monoxide
Timepoint [14] 310528 0
Baseline, before and after pre-quitting phase, week 4,8, and 12 of smoking cessation phase. Week four of open-label phase.
Secondary outcome [15] 310530 0
Side effects: Participants complete a questionnaire that asks if they have had a range of 19 symptoms, e.g. urinary retention, blurred vision, constipation, weight gain, if they have experienced any other symptoms, and what they did to remedy any symptoms they had experienced.
This side effect questionnaire is used by researchers in the Mental Health and Nutrition Research Group at the University of Canterbury to monitor side effects when participants consume capsules.
Timepoint [15] 310530 0
Baseline, before and after pre-quitting phase, weeks 4,8, and 12 of smoking cessation phase. Week two and four of open-label phase. Assessed using a self-report questionnaire
Secondary outcome [16] 310531 0
Capsule compliance. Counting any left over capsules.
Timepoint [16] 310531 0
Daily throughout pre-quitting phase, smoking cessation phase and open-label phase.
Secondary outcome [17] 310532 0
Continious abstinence throughout four week open-label phase. Assessed using self report and CO readings.
Timepoint [17] 310532 0
End of four week open-label phase.
Secondary outcome [18] 310533 0
Continious abstinence from two (grace period) to four weeks of open-label phase. Assessed using self report diary and CO reading with Bedfont Smokerlyzer.
Timepoint [18] 310533 0
End of four week open-label phase.
Secondary outcome [19] 310551 0
Abstinence at six month follow-up. Assessed using self report.
Timepoint [19] 310551 0
Six month follow-up
Secondary outcome [20] 313059 0
Blood Pressure (mm Hg). Measured using an automatic sphygmomanometer.
Timepoint [20] 313059 0
Baseline, before and after pre-quitting phase, 4,8, and 12-weeks of the smoking cessation phase. Four weeks after the open-label phase.
Secondary outcome [21] 317457 0
Abstinence and smoking habits (cigarettes per day) at 12-month follow-up.
Assessed with email and/or telephone call.
Timepoint [21] 317457 0
12 months after quit day.

Eligibility
Key inclusion criteria
1) 18 years old or over 2) meet a 'current smoking' criteria of smoking at least three cigarettes a day for the past year 3) no serious medical conditions that require treatment during trial period 4) are not on psychoactive medication. Participants must be medication free for at least four weeks prior to beginning the trial.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1) under 18 years old 2) not a 'current smoker' of three or more cigarettes a day for the past year 3) on any psychoactive medication 4) any serious medical condition

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Provided that an individual meets the inclusion criteria and does not meet exclusion criteria, the person is allocated the next available participant number when they consent to take part in the study. Randomization to active or placebo will be done by a research assistant outside of the laboratory and the randomization list is given to the pharmacist. All capsules (ie active ingredient or placebo) have been pre-packaged by a pharmacist who holds the randomization code. A sealed envelope is contained within each pill package only to be opened in an emergency (ie patient deteriorates significantly), this means only the blind for that participant would be broken.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomization for pill allocation will be done by a research assistant using randomization.com. Randomization.com uses block randomization. A pharmacist will receive a list of participant numbers and whether they are allocated to active or a placebo condition.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The RCT aims to recruit 80 participants (40 in DEN group, 40 in the placebo group). Participant number are based on initial pilot results, using power = 0.8 to detect a large effect size (0.8), with two tailed a=0.05.

Descriptive statistics will be calculated for demographic measures of the participants. Time series graphs will be constructed to show intensity and trajectory of change in MPSS withdrawal patterns during smoking cessation overtime. Computer generated trend and level lines will be used to further analyse data. Visual analysis (Modified Brinley Plots) will compare the DEN group and placebo. Patterns of individual change in monthly questionnaire ratings over study phases within groups will be examined using modified Brinley plots. Cohen’s d(between)(within) effect size will be used in the current study. Categorical outcome (quit/not-quit) will be compared using Chi-squared tests with odds ratio (ORs) and 95% confidence intervals and logistic regression. Hierarchical multiple regression will be used to evaluate how individual differences in psychological measures effect withdrawal symptoms and smoking abstinence rates throughout the study.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
9/03/2015
Actual
9/03/2015
Date of last participant enrolment
Anticipated
Actual
21/07/2015
Date of last data collection
Anticipated
Actual
21/07/2016
Sample size
Target
80
Accrual to date
Final
107
Recruitment outside Australia
Country [1] 6355 0
New Zealand
State/province [1] 6355 0
Canterbury

Funding & Sponsors
Funding source category [1] 289962 0
University
Name [1] 289962 0
University of Canterbury
Country [1] 289962 0
New Zealand
Primary sponsor type
University
Name
University of Canterbury
Address
Private bag 4800
Christchurch 8140
Country
New Zealand
Secondary sponsor category [1] 288653 0
None
Name [1] 288653 0
Address [1] 288653 0
Country [1] 288653 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 291684 0
University of Canterbury Human Ethics Committee
Ethics committee address [1] 291684 0
Ethics committee country [1] 291684 0
New Zealand
Date submitted for ethics approval [1] 291684 0
22/01/2015
Approval date [1] 291684 0
11/02/2015
Ethics approval number [1] 291684 0
2015/11

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 51474 0
Miss Phillipa Kate Newton
Address 51474 0
Department of Psychology
University of Canterbury
Private Bag 4800
Christchurch 8041
Country 51474 0
New Zealand
Phone 51474 0
+64 (0)3 364 2987 ext. 7705
Fax 51474 0
Email 51474 0
[email protected]
Contact person for public queries
Name 51475 0
Phillipa Newton
Address 51475 0
Department of Psychology
University of Canterbury
Private Bag 4800
Christchurch 8041
Country 51475 0
New Zealand
Phone 51475 0
+64 (0)3 364 2987 ext. 7705
Fax 51475 0
Email 51475 0
[email protected]
Contact person for scientific queries
Name 51476 0
Phillipa Newton
Address 51476 0
Department of Psychology
University of Canterbury
Private Bag 4800
Christchurch 8041
Country 51476 0
New Zealand
Phone 51476 0
+64 (0)3 364 2987 ext. 7705
Fax 51476 0
Email 51476 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Study results articleYes Reihana, P. K., Blampied, N. M., & Rucklidge, J. J... [More Details]

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseNovel Mineral-Vitamin Treatment for Reduction in Cigarette Smoking: A Fully Blinded Randomized Placebo-Controlled Trial.2019https://dx.doi.org/10.1093/ntr/nty168
N.B. These documents automatically identified may not have been verified by the study sponsor.